Literature DB >> 22481744

FDA regulation of invasive neural recording electrodes: a daunting task for medical innovators.

Cristin Welle1, Victor Krauthamer.   

Abstract

The U.S. Food and Drug Administration (FDA) is charged with assuring the safety and effectiveness of medical devices. Before any medical device can be brought to market, it must comply with all federal regulations regarding FDA processes for clearance or approval. Navigating the FDA regulatory process may seem like a daunting task to the innovator of a novel medical device who has little experience with the FDA regulatory process or device commercialization. This review introduces the basics of the FDA regulatory premarket process, with a focus on issues relating to chronically implanted recording devices in the central or peripheral nervous system. Topics of device classification and regulatory pathways, the use of standards and guidance documents, and optimal time lines for interaction with the FDA are discussed. Additionally, this article summarizes the regulatory research on neural implant safety and reliability conducted by the FDA's Office of Science and Engineering Laboratories (OSEL) in collaboration with Defense Advanced Research Projects Agency (DARPA) Reliable Neural Technology (RE-NET) Program. For a more detailed explanation of the medical device regulatory process, please refer to several excellent reviews of the FDA's regulatory pathways for medical devices [1]-[4].

Mesh:

Year:  2012        PMID: 22481744     DOI: 10.1109/MPUL.2011.2181022

Source DB:  PubMed          Journal:  IEEE Pulse        ISSN: 2154-2287            Impact factor:   0.924


  3 in total

1.  Rapid evaluation of the durability of cortical neural implants using accelerated aging with reactive oxygen species.

Authors:  Pavel Takmakov; Kiersten Ruda; K Scott Phillips; Irada S Isayeva; Victor Krauthamer; Cristin G Welle
Journal:  J Neural Eng       Date:  2015-01-28       Impact factor: 5.379

2.  The development of neural stimulators: a review of preclinical safety and efficacy studies.

Authors:  Robert K Shepherd; Joel Villalobos; Owen Burns; David A X Nayagam
Journal:  J Neural Eng       Date:  2018-05-14       Impact factor: 5.379

3.  Adjacent regenerative peripheral nerve interfaces produce phase-antagonist signals during voluntary walking in rats.

Authors:  Daniel Ursu; Andrej Nedic; Melanie Urbanchek; Paul Cederna; R Brent Gillespie
Journal:  J Neuroeng Rehabil       Date:  2017-04-24       Impact factor: 4.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.